# Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers

> **NCT02269215** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 73 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIII 890 CL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02269215
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** 2000-09
- **Final completion:** —
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2014-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02269215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02269215, "Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02269215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*